TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) CEO Waleed H. Hassanein sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

TransMedics Group Price Performance

Shares of TMDX traded down $0.62 during trading hours on Thursday, reaching $87.24. 692,313 shares of the stock traded hands, compared to its average volume of 688,977. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $99.63. The company's 50-day moving average price is $83.01 and its two-hundred day moving average price is $72.88.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The company had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group's revenue for the quarter was up 158.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.21) EPS. Research analysts expect that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Institutional Trading of TransMedics Group

Hedge funds have recently bought and sold shares of the stock. Ancora Advisors LLC purchased a new stake in TransMedics Group in the 1st quarter worth $38,000. First Horizon Advisors Inc. lifted its stake in TransMedics Group by 45.1% in the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock worth $41,000 after purchasing an additional 169 shares in the last quarter. Belpointe Asset Management LLC lifted its stake in TransMedics Group by 51.6% in the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company's stock worth $42,000 after purchasing an additional 190 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of TransMedics Group by 595.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 598 shares of the company's stock worth $50,000 after buying an additional 512 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in shares of TransMedics Group in the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Oppenheimer raised their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a report on Tuesday, February 27th. Morgan Stanley lifted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. Finally, Piper Sandler initiated coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They set an "overweight" rating and a $95.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $102.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.